Related Experiment Videos
New (Very High) Prices on Old Drugs
Saate Shakil1,2, Rita F Redberg1,3
1Department of Medicine, University of California, San Francisco.
JAMA Internal Medicine
|September 12, 2017
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Coverage Limitations for Use of Urine Drug Testing in a State Medicaid Program.
JAMA network open·2026
From Registry to Reality: Opportunities to Enhance Post-market Surveillance of High-Risk Medical Devices Comment on "Quality and Utility of European Cardiovascular and Orthopaedic Registries for the Regulatory Evaluation of Medical Device Safety and Performance Across the Implant Lifecycle: A Systematic Review".
International journal of health policy and management·2026
Evaluation of Payer Policies to Reduce Low-Value Medical Device-Based Procedure Use.
JAMA health forum·2025
Insurer Coverage of Invasive Coronary Angiography and Percutaneous Coronary Intervention for Stable Coronary Artery Disease Compared With Guidelines and Landmark Trials in the United States.
Circulation. Cardiovascular quality and outcomes·2025
INSPECT-SR: a tool for assessing trustworthiness of randomised controlled trials.
medRxiv : the preprint server for health sciences·2025
Medicare Advantage and Type 2 Diabetes Outcomes.
JAMA internal medicine·2026
Continuous Glucose Monitoring in Type 2 Diabetes and Beyond: A Review.
JAMA internal medicine·2026
An Indigenous Food Is Medicine Intervention: The MUTTON-HF Randomized Clinical Trial.
JAMA internal medicine·2026
Understanding non-medical prescribers' antimicrobial prescribing and stewardship competency: A scoping review.
Research in social & administrative pharmacy : RSAP·2026
False Friends in Fluorescence - Simple HPLC Evaluation of False Positive Fragment Hits in a DiFMUP Assay for Protein Tyrosine Phosphatase 1B.
Drug design, development and therapy·2026
Rebalancing innovation, affordability, and access for orphan drugs in the European Union.
The Lancet regional health. Europe·2026
Clinical and Economic Burden of Diseases with Accelerated Approval Therapies: Evidence of Unmet Patient Need.
Therapeutic innovation & regulatory science·2026